Current Report Filing (8-k)
February 22 2018 - 2:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 20,
2018
PSYCHEMEDICS CORPORATION
(Exact Name of Registrant as Specified in its Charter)
Delaware
|
1-13738
|
58-1701987
|
(State or Other Jurisdiction
|
(Commission File Number)
|
(I.R.S. Employer
|
of Incorporation)
|
|
Identification No.)
|
|
|
|
125 Nagog Park, Acton, Massachusetts
|
|
01720
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(978) 206-8220
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected
not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
|
ITEM 5.02(e)
|
COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS
|
1.
On February 20, 2018, Psychemedics Corporation (the “Company”) entered into an amended change in control severance
agreement with Raymond C. Kubacki, Chairman, Chief Executive and President of the Corporation. The agreement is for a five year
term commencing on February 20, 2018. It provides that if, during the five-year term, the Company terminates Mr. Kubacki’s
employment for any reason other than for Cause (as defined in the agreement), death or disability (as defined in the agreement)
or if Mr. Kubacki terminates his employment for Good Reason (as defined below), in either case, within twelve months following
a Change in Control (as defined in the agreement), he will be entitled to receive Termination Pay (as defined below) for a period
of twelve months from the date of such termination, except that Good Reason termination solely on account of a change in location
would give rise to Termination Pay for a period of six months rather than twelve months. Termination Pay includes average monthly
base salary and cash bonus compensation paid or accrued during the twelve month period preceding such termination. Good Reason
includes a change in Mr. Kubacki’s title, a reduction in his base salary then in effect, a material decrease in his duties
or responsibilities, or a change of location. The agreement also prohibits Mr. Kubacki from working for a competitor of the Company
or from soliciting employees of the Company during the period he is eligible to receive Termination Pay under the agreement. Mr.
Kubacki’s agreement was in replacement of his agreement executed in 2013, which had a five-year term and was due to expire
in March, 2018.
2.
On February 20, 2018, the Company also entered into a change in control severance agreement with Michael I. Schaffer, Ph.D.,
Vice President of Laboratory Operations of the Company. Dr. Shaffer’s agreement is also for a five year term commencing on
February 20, 2018. It provides that if, during the five-year term, the Company terminates Dr. Schaffer’s employment for any
reason other than for Cause (as defined in the agreement), death or disability (as defined in the agreement) or if Dr. Schaffer
terminates his employment for Good Reason (as defined below), in either case, within twelve months following a Change in Control
(as defined in the agreement), he will be entitled to receive Termination Pay (as defined below) for a period of twelve months
from the date of such termination. Termination Pay includes average monthly base salary and cash bonus compensation paid or accrued
during the twelve month period preceding such termination. Good Reason includes a reduction in Dr. Schaffer’s base salary
then in effect, or a material decrease in his duties or responsibilities. The agreement also prohibits Dr. Schaffer from working
for a competitor of the Company or from soliciting employees of the Company during the period he is eligible to receive Termination
Pay under the agreement. Dr. Schaffer’s agreement was in replacement of his agreement executed in 2013, which had a five-year
term and was due to expire in March, 2018
3.
The foregoing summary of the change in control severance agreements with Mr. Kubacki and Dr. Schaffer does not purport to
be complete and is qualified in its entirety by reference to the change in control severance agreements with such executives which
are attached hereto as Exhibits 10.1 and 10.2 and are incorporated by reference into this report.
|
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS.
|
The following exhibits are filed herewith:
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
PSYCHEMEDICS CORPORATION
|
|
|
|
|
|
|
Dated: February 22, 2018
|
|
By:
|
/s/ Neil Lerner
|
|
|
|
Neil Lerner, Vice President - Finance
|
|
|
|
4
Psychemedics (NASDAQ:PMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Psychemedics (NASDAQ:PMD)
Historical Stock Chart
From Sep 2023 to Sep 2024